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Phototherapy is a powerful, noninvasive approach
for cancer treatment, with several agents currently
in clinical use. Despite the progress and promise,
most current phototherapy agents have serious
side effects as they can lead to damage to healthy tis-
sue, even when the photosensitizers are fused to tar-
geting molecules due to nonspecific light activation
of the unbound photosensitizer. To overcome these
limitations, we developed a phototherapy agent that
combines a functional ligand and a near infrared
phthalocyanine dye. Our target is type 2 cannabinoid
receptor (CB2R), considered an attractive therapeu-
tic target for phototherapy given it is overexpressed
bymany types of cancers that are located at a surface
or can be reached by an endoscope. We show that
our CB2R-targeted phototherapy agent, IR700DX-
mbc94, is specific for CB2R and effective only when
bound to the target receptor. Overall, this opens up
the opportunity for development of an alternative
treatment option for CB2R-positive cancers.
INTRODUCTION
The therapeutic value of light has been known for more than
3,000 years, and a systematic understanding of phototherapy
has only been established over the past century (Dolmans
et al., 2003; Tong and Kohane, 2012). Two types of phototherapy
have been particularly well studied: photodynamic therapy (PDT)
and photothermal therapy (PTT). As the conventional photother-
apy, PDT destroys neoplastic lesions with reactive oxygen
species (ROS), which are produced by using light of specific
wavelengths to irradiate the PDT agents (Oleinick et al., 2002).
The main classes of PDT agents include porphyrin derivatives,
chlorins, porphycenes, and phthalocyaines (De Rosa and Bent-
ley, 2000). PDT has now been clinically used as a noninvasive338 Chemistry & Biology 21, 338–344, March 20, 2014 ª2014 Elsevietechnique for cancer treatment, mainly in dermatology, ophthal-
mology, and gastroenterology. To date, several PDT agents
have been approved by the FDA to treat cancer, such as Photo-
frin, Levulan, Metvix, and Foscan (Triesscheijn et al., 2006). PTT
ablates tumors by converting photonic energy to heat instead of
ROS (Jori and Spikes, 1990). By causing temperatures to rise,
PTT leads to irreversible damage to cancer cells (Tong and
Kohane, 2012).
Despite the advances in phototherapy techniques, PDT and
PTT have significant limitations. Most existing PDT and PTT
agents lack tumor selectivity; therefore, normal tissues can
also be damaged, leading to considerable side effects (Mitsu-
naga et al., 2011; Tong and Kohane, 2012). Although targeting
molecules, such as antibodies (Copland et al., 2004; Lukia-
nova-Hleb et al., 2011), antibody fragments (Qian et al., 2008),
receptor ligands (Chen et al., 2013), and peptides (Kim et al.,
2011; Kumar et al., 2012) can be attached to photosensitizers
for targeted delivery, unbound photosensitizers can still damage
normal tissues upon light irradiation. As such, it is critical to
develop highly target-selective phototherapy approaches.
Recently, Mitsunaga et al. (2011) described a highly target-
selective phototherapy approach, photoimmunotherapy (PIT),
which uses target-specific photosensitizers based on mono-
clonal antibodies coupled with a near infrared (NIR) phthalocya-
nine dye, IR700DX. Unlike conventional PIT technique (Goff
et al., 1991;Mewet al., 1983), thenewPITagents reportedbyMit-
sunagaet al. (2011) caused effective therapeutic effect onlywhen
they bound to target cancer cells while unbound sensitizers did
not produce phototoxicity. Considering the high cost and long
circulation time of antibodies (Olafsen and Wu, 2010), we set
out to investigate whether target-selective phototherapy can be
achievedusingsmall photosensitizersbasedon receptor ligands.
Here, we report a type 2 cannabinoid receptor (CB2R)-
targeted phototherapy study using a phototherapy agent,
IR700DX-mbc94. CB2R is a transmembrane G protein-coupled
receptor (GPCR) that was first cloned in 1993 (Munro et al.,
1993). Under basal conditions, CB2R is expressed mainly in
immune cells while the expression in other types of cells is low
to undetectable (Munro et al., 1993; Sexton et al., 2011). How-
ever, CB2R is overexpressed by many types of cancers, suchr Ltd All rights reserved
Figure 1. Synthesis and Photophysical Properties of IR700DX-mbc94
(A) Synthesis of IR700DX-mbc94.
(B) Absorption (solid) and emission (dotted) spectra of IR700DX-mbc94 in MeOH at a concentration of 1 mM (lex = 640 nm).
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CB2 Receptor-Targeted Phototherapyas prostate, skin, liver, and breast cancer, and moreover,
the expression levels of CB2R appear to be associated with
tumor aggressiveness (Qamri et al., 2009; Velasco et al., 2012;
Xu et al., 2006). Such upregulation of the receptor in cancer
cells provides an opportunity to specifically target CB2R
and thus lower the side effects. Importantly, because many
types of the CB2R positive cancers are superficial or can be
reached by endoscope, CB2R has great potential as a photo-
therapy target. We previously reported an NIR CB2R-targeted
imaging probe, NIR-mbc94, and validated its specific binding
to CB2R in vitro (Bai et al., 2008; Sexton et al., 2011). More
recently, we reported the CB2R-targeted in vivo optical imaging
using another NIR fluorescent probe, NIR760-mbc94 (Zhang
et al., 2013). In this study, we developed IR700DX-mbc94 as
the CB2R receptor-targeted photosensitizer. We found that
IR700DX-mbc94 caused significant cancer cell death only
when bound to the target receptor. This photosensitizer appearsChemistry & Biology 21, 3to have great potential in cancer phototherapy with high target
specificity.
RESULTS AND DISCUSSION
IR700DX-mbc94 was synthesized by coupling IR700DX with
mbc94, a conjugable CB2R ligand previously reported by us
(Figure 1A) (Bai et al., 2008; Sexton et al., 2011). As displayed
in Figure 1B, IR700DX-mbc94 exhibited an intense NIR absorp-
tion centered at 682 nm and maximum emission at 690 nm in
methanol. The relatively small Stokes shift is typical for phthalo-
cyanine dyes (Li et al., 2008).
To study the phototherapeutic effect of IR700DX-mbc94, we
used CB2-mid DBT cells, a transfected mouse malignant astro-
cytoma cell line that expresses CB2R at the endogenous levels.
Wild-type (WT) DBT cells that have no CB2R expression were
used as negative control (Cudaback et al., 2010).38–344, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 339
Figure 2. In Vitro CB2R Saturation Binding Assay of IR700DX-mbc94
Cells were preincubated with (nonspecific binding) or without (total binding)
1 mM of the blocking agent SR144528 for 1 hr and then incubated overnight
with an increasing concentration of IR700DX-mbc94 at 37C. Cells were then
rinsed and the fluorescence intensity was recorded. The specific binding was
obtained by the subtraction of nonspecific binding from the total binding. The
dissociation constant (KD) and receptor density (Bmax) were estimated from
the nonlinear fitting of specific binding versus IR700DX-mbc94 concentration
using Prism software. Each data point represents the mean ± SD based on
triplicate samples.
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absence of light irradiation in CB2-mid DBT cells, we used
the CellTiter-Glo Luminescent Cell Viability Assay kit. As shown
in Figure S1A, available online, cells incubated with as high as
10 mMof IR700DX-mbc94 exhibited comparable low cytotoxicity
to those treated with indocyanine green (ICG), the only Food and
Drug Administration (FDA)-approved NIR fluorescent dye. We
also found that the cytotoxic effect of IR700DX-mbc94 was
significantly lower than that of mbc94 alone. The relatively high
cytotoxicity of mbc94 was expected, as it had been reported
that many CB2R ligands exhibited anticancer properties
(Velasco et al., 2012). It is possible that attaching IR700DX to
mbc94 changed the binding profile of mbc94, leading to
decreased CB2R activation and therapeutic effect. In addition,
to show the toxicity of IR700DX-mbc94 in noncancerous cells
that express the CB2R, we used CB2R-transfected Chinese
hamster ovarian (CHO-K1/CB2) cells (Gertsch et al., 2008). The
cytotoxicity of IR700DX-mbc94 in CHO-K1/CB2 cells was as
low as that in CB2-mid DBT cells (Figure S1B). These combined
data suggest that IR700DX-mbc94 is a safe agent in the absence
of light irradiation.
To determine IR700DX-mbc94’s binding affinity to CB2R in
intact cells, we used an in vitro saturation binding assay to
measure the equilibrium dissociation constant (KD) and the
maximum specific binding (Bmax). A representative saturation
binding curve is shown in Figure 2. From this data, we esti-
mated that IR700DX-mbc94 bound to CB2R with a KD of
42.0 nM (±19.6) and Bmax of 650.5 pmol/mg (±93.1). Bmax
over KD value was 15, indicating favorable binding for
in vitro phototherapy experiments and future in vivo imaging
studies.
We then carried out in vitro phototherapy experiments using
IR700DX-mbc94 and light irradiation. CB2-mid DBT cells were
incubated with 5 mM of IR700DX-mbc94 at 37C overnight.
Cells were then washed twice and irradiated with light from a
light-emitting diode (LED) light source at wavelengths of 670–
710 nm (peak at 690 nm) and a power density of 30 mW/cm2.
As shown in Figure 3A, CB2-mid DBT cells incubated with
IR700DX-mbc94 did not show significant cell death (1.6% ±
1.4%) without light irradiation; however, irradiation of light for340 Chemistry & Biology 21, 338–344, March 20, 2014 ª2014 Elsevie20 min eradicated 79.5% ± 2.4% of the living cells. Similarly,
there was little cell death associated with light irradiation in
the absence of IR700DX-mbc94 (10.4% ± 2.0%). In addition,
unbound IR700DX-mbc94 did not appear to contribute to the
therapeutic effect, as we observed a similar level of cell death
whether unbound IR700DX-mbc94 was washed (79.5% ±
2.4% cell death) or not (76.2% ± 5.3% cell death) (Figure 3B).
We found that as much as 87.2% ± 2.0% of IR700DX-mbc94
was washed out (Figure 3C). To further investigate the target-
specific phototherapy effect of IR700DX-mbc94, we compared
phototoxicity between free IR700DX dye and IR700DX-mbc94.
As expected, CB2-mid DBT cells incubated with the same
concentration of free IR700DX (5 mM) showed minimal cell
death under light irradiation, whether the cells were washed
(6.0% ± 4.5% cell death) or not (6.7% ± 3.7% cell death) (Fig-
ure 3D). We also studied the role of IR700DX-mbc94 binding
in phototherapy by comparing the therapeutic effect on CB2-
mid and WT DBT cells. As shown in Figure 3E, WT-DBT cells
treated with IR700DX-mbc94 followed by light irradiation
showed significantly less cell death than CB2-mid DBT cells
(46.7% ± 7.9% versus 79.5% ± 2.4%, p = 0.002). This provides
additional evidence that the ability of IR700DX-mbc94 to kill
cancer cells required receptor binding. These combined data
indicate that IR700DX-mbc94 causes cell death in a target-
specific manner. Additionally, increased cell death was
observed with an increased dose of light irradiation, higher
concentration of IR700DX-mbc94 or longer incubation time
(Figure S2). Furthermore, the potential of IR700DX-mbc94 for
treating tumors in vivo was preliminarily assessed using a
mouse tumor model. The experiments were approved by Uni-
versity of Pittsburgh Institutional Animal Care and Use Commit-
tee. CB2-mid DBT cells were subcutaneously injected into mice
to grow tumor. We found that tumor growth was significantly
inhibited in the phototherapy-treated group using IR700DX-
mbc94 compared with the nontreatment group (average tumor
volume: 134.98 mm3 in phototherapy-treated mice versus
780.16 mm3 in untreated mice at day 7, p = 0.03) (Figure S3).
This indicates that IR700DX-mbc94 has great potential as a
phototherapy agent.
To study the mechanism underlying phototherapy of
IR700DX-mbc94, we first investigated whether the therapeutic
effect correlated with the generation of ROS, which trigger
cell death during PDT. There are two types of PDT mecha-
nisms: type I produces free radicals such as hydroxyl radicals
(HO$), which can be inhibited by 1,3-dimethyl-2-thiourea
(DMTU) (Sagone et al., 1989), and type II produces singlet
oxygen (1O2) (Huang et al., 2012), which can be scavenged
by sodium azide (NaN3) (Mitsunaga et al., 2011). Studies have
shown that DMTU could pass through cell membrane (Lai
et al., 1999) and NaN3 is an effective scavenger of intracellularly
generated singlet oxygen (Sparrow et al., 2002). Therefore,
although IR700DX-mbc94 is primarily located inside the cells
as discussed below, DMTU and NaN3 are effective ROS inhib-
itors. We found that treatment of CB2-mid DBT cells with DMTU
(1 mM) did not significantly affect the therapeutic effect of
IR700DX-mbc94 under light irradiation (cell death 80.5% ±
7.6% with DMTU versus 79.4% ± 1.2% without DMTU, Fig-
ure 3F). In addition, the use of NaN3 (50 mM) did not reverse
the therapeutic effect either (cell death 87.1% ± 0.1% withr Ltd All rights reserved
Figure 3. In Vitro Phototherapy Using IR700DX-mbc94
(A) Comparison of phototherapy effect on CB2-mid DBT cells among four groups: IR700DX-mbc94 () and irradiation (); IR700DX-mbc94 () and irradiation (+);
IR700DX-mbc94 (+) and irradiation (); and IR700DX-mbc94 (+) and irradiation (+).
(B) Phototherapy effect on CB2-mid DBT cells incubated with 5 mM of IR700DX-mbc94 with or without wash.
(C) Quantification of unbound (photosensitizer that was washed out) and bound (remaining photosensitizer after washing) IR700DX-mbc94 using fluorescence.
(D) Phototherapy effect compared between CB2-mid DBT cells treated with IR700DX-mbc94 (5 mM) and free IR700DX dye (5 mM).
(E) Comparison of cell death caused by IR700DX-mbc94 exposed to light irradiation between CB2-mid DBT and WT-DBT cells (**p < 0.01).
(F) Effect of DMTU (1 mM) inhibition on cell death caused by IR700DX-mbc94 phototherapy.
(G) Effect of sodium azide (50 mM) inhibition on cell death caused by IR700DX-mbc94 phototherapy. Each data point represents the mean ± SD based on
triplicate samples.
See also Figures S2 and S3.
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CB2 Receptor-Targeted PhototherapyNaN3 versus 79.5% ± 2.4% without NaN3, Figure 3G). Based
on the above data, it appears that the phototherapeutic mech-
anism of IR700DX-mbc94 is distinct from the traditional PDT
effect. However, further studies are needed to elucidate the
mechanism of IR700DX-mbc94’s therapeutic effect, which are
beyond the scope of this study.
To visualize cell death caused by phototherapy of IR700DX-
mbc94, CB2-mid DBT cells were imaged under fluorescence
microscopy with or without phototherapy (Figure 4). Cells
treated with IR700DX-mbc94 in the absence of irradiation
exhibited a normal morphology, and IR700DX-mbc94 was
mainly located in the cytoplasm. In contrast, cells treated
with IR700DX-mbc94 with light irradiation showed morpholog-
ical changes typically observed in necrotic cell death, such asChemistry & Biology 21, 3small blebs formation, cytoplasmic swelling, cell membrane
rupture, and cell contents’ release (Golstein and Kroemer,
2007). These morphological changes are similar to those pre-
viously reported for PIT, in which an IR700DX-conjugated
monoclonal antibody was used as the PIT probe (Mitsunaga
et al., 2011). To investigate whether internalization of
IR700DX-mbc94 played an important role in the phototherapy
effects, we used LysoTracker to find out if some IR700DX-
mbc94 molecules were internalized and ended in lysosomal
degradation. We observed certain colocalization (orange color)
of LysoTracker and IR700DX-mbc94 fluorescence after 2 hr of
incubation, indicating that part of IR700DX-mbc94 was
internalized. In addition, IR700DX-mbc94 was shown to be
primarily localized in the cytoplasm (Figures 4 and S4), which38–344, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 341
Figure 4. Fluorescence Microscopy of CB2-
Mid DBT Cells with or without Phototherapy
CB2-mid DBT cells were treated with 5 mM of
IR700DX-mbc94 at 37C overnight, with or
without light irradiation (30 mW/cm2, 20 min).
Upper panel: IR700DX-mbc94 (red fluorescence)
and DAPI (blue fluorescence) images. Lower
panel: differential interference contrast (DIC)
images. With phototherapy treatment, cells
experienced typical necrotic cell morphological
changes, such as bleb formation (white arrow-
head), cell membrane rupture and releasing of
cells’ contents (red arrowhead). Scale bar repre-
sents 20 mm.
See also Figure S4.
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ily located at intracellular sites in certain cell lines (Castaneda
et al., 2013). Based on these observations, it is likely that
some IR700DX-mbc94 molecules bound to the surface CB2R
and internalized, whereas the majority of IR700DX-mbc94
molecules diffused into the cells and bound to intracellular
CB2R. We also noted that compared with IR700DX-based PIT
(Mitsunaga et al., 2011), 10-fold of light was needed in CB2R-
targeted phototherapy to achieve similar therapeutic effects.
This is likely due to the relatively low binding affinity of
IR700DX-mbc94 to CB2R compared with that of the anti-
body-antigen binding.
SIGNIFICANCE
We report a type 2 cannabinoid receptor-targeted photo-
therapy study using a photosensitizer (IR700DX-mbc94)
based on a NIR phthalocyanine dye and a functional CB2R-
targeted molecule. IR700DX-mbc94 was only effective
when bound to the target receptor and produced no
phototoxicity when not bound, and the extent of the photo-
therapeutic effect of IR700DX-mbc94 was much less in
CB2R– than in CB2R+ cells, suggesting a highly specific
receptor-targeted phototherapymechanism.Overall, recep-
tor-targeted phototherapy provides a facile, target-specific
approach based on small molecule photosensitizers with
the advantages of low cost, easy delivery, and fast clear-
ance. In addition, the discovery of receptor-targeted
phototherapy may open opportunities to develop receptor
targeted phototherapy techniques in general because
various receptor ligands or peptides can be conjugated to
IR700DX as potential phototherapy agents. Therefore,
IR700DX-mbc94 appears to be an attractive phototherapy
and therapeutic monitoring agent for the treatment of
cancers.342 Chemistry & Biology 21, 338–344, March 20, 2014 ª2014 Elsevier Ltd All rights reservedEXPERIMENTAL PROCEDURES
Synthesis of IR700DX-mbc94
A mixture of IR700DX-NHS ester (2.5 mg,
1.28 mmol) and mbc94 (3 mg, 5.08 mmol) in
DMSO (1 ml) was stirred at room temperature
under argon for 24 hr in the absence of light.
DMSO was removed by lyophilization, andthe residue was washed by ethyl acetate (10 ml 3 3) and dried by
lyophilization.
In Vitro Saturation Binding Assay of IR700DX-mbc94
We carried out intact cell saturation binding assay to determine CB2R binding
affinity to IR700DX-mbc94 as previously reported (Zhang et al., 2013).
Cytotoxicity
CB2-mid DBT cells were treated with indicated concentration of IR700DX-
mbc94, or mbc94, without light irradiation for 24 hr in a water-jacketed incu-
bator. ICG (Sigma-Aldrich) was used as the negative control and doxorubicin
hydrochloride (Fisher Scientific) was used as the positive control. To test the
toxicity of the IR700DX-mbc94 in cells that express the CB2 receptor but are
not tumoral, CHO-K1/CB2 cells were treated with indicated concentration of
IR700DX-mbc94 for 24 hr. Cell viability was determined by CellTiter-Glo Lumi-
nescent Cell Viability Assay kit (Promega) according to the manufacturer’s
instructions.
In Vitro Phototherapy
CB2-mid (CB2R+) and WT (CB2R) DBT cells were grown to confluence in
T75 flasks, harvested, seeded into 96-well optical plates, and incubated in
a water-jacketed incubator for 24 hr prior to treatment. Each type of DBT
cells was incubated with 5 mM of IR700DX-mbc94 at 37C overnight. Cells
were then irradiated with light from an LED light source (L690-66-60, Maru-
beni America) at wavelengths of 670–710 nm (peak at 690 nm) and a power
density of 30 mW/cm2, as measured with an optical power meter (PM100,
Thorlabs). We compared the number of dead cells after the following treat-
ments: IR700DX-mbc94 () and irradiation (); IR700DX-mbc94 () and irra-
diation (+); IR700DX-mbc94 (+) and irradiation (); and IR700DX-mbc94 (+)
and irradiation (+). In addition, to investigate whether a higher amount of
IR700DX-mbc94 in the surrounding medium will induce more cell death,
we compared the phototherapy effect in cells that were washed and not
washed. To quantify the unbound and bound IR700DX-mbc94, we measured
the fluorescence intensities of the combined serum-free washing medium
and the washed cells. Furthermore, we compared CB2-mid DBT cells treated
with free IR700DX dye (5 mM) with those treated with IR700DX-mbc94 (5 mM).
The CB2R-targeted phototherapy effect was then evaluated between
CB2-mid and WT DBT cells. To study whether the mechanism of photother-
apy differs from that of PDT, a free radical scavenger DMTU (1 mM) or a 1O2
quencher NaN3 (50 mM) was added with IR700DX-mbc94 to CB2-mid
Chemistry & Biology
CB2 Receptor-Targeted PhototherapyDBT cells right before 20 min of light irradiation. We also tested whether the
phototherapeutic effect is dependent on the dose of light irradiation, incuba-
tion time, and concentration of IR700DX-mbc94.
Fluorescent Microscopy
CB2-mid DBT cells were incubated with 5 mM of IR700DX-mbc94 at 37
C
overnight and then washed with fetal bovine serum (FBS)-free medium
once. The cells were divided into two groups, with or without light
irradiation (30 mW/cm2, 20 min). Cell fluorescent staining was carried out
as previously reported (Zhang et al., 2013). IR700DX-mbc94 fluorescent
images were captured with a NIR camera equipped with a Cy5 filter set
(excitation/emission: 625–655 nm/665–715 nm). Nuclear images were ob-
tained with a DAPI filter set (excitation/emission: 335–383 nm/420–
470 nm). Differential interference contrast (DIC) images were obtained
through Trans light DIC.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
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